Neoadjuvant therapy in patients with left-sided resectable pancreatic cancer
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by E. Rangelova on X:
“The impact of neoadjuvant therapy in patients with left-sided resectable PDAC:
- International multicenter study2,282 pts.
- Neoadj. CTx improves OS for left-sided PDAC.
- higher benefit in pts w/ large tumors & high CA19-9.
- We need prospective studies.”
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study.
Authors: E. Rangelova, et al.
Arndt Vogel, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023